What do a synthetic chemist, a medical imaging expert, and a neurologist have in common? They’re coming together in the Biomedical Imaging Center at the Beckman Institute for Advanced Science and Technology to develop better diagnostic tools and imaging agents to detect early-stage Alzheimer’s disease and other neurodegenerative diseases.
Optimind Pharma Closes First Tranche of Private Placement | Psychedelic Invest
Toronto, Ontario–(Newsfile Corp. – July 8, 2024) – Optimind Pharma Corp. (CSE: OMND) (“Optimind” or the “Company”) announces it has closed the first trance of
July 9, 2024